TIBSOVO 250 mg/1
ivosidenib · TABLET, FILM COATED · Servier Pharmaceutical LLC
Tibsovo (ivosidenib) is an oral tablet used to treat certain types of acute myeloid leukemia and cholangiocarcinoma by inhibiting an enzyme called isocitrate dehydrogenase 1. It works by blocking a specific genetic mutation that can drive the growth of these cancers.
Key Facts
- Brand Name
- TIBSOVO
- Generic Name
- ivosidenib
- NDC Code (Product)
72694-617- Manufacturer
- Servier Pharmaceutical LLC
- Strength
- 250 mg/1
- Dosage Form
- TABLET, FILM COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA211192
- Drug Class
- Isocitrate Dehydrogenase 1 Inhibitor [EPC]
- Marketing Start
- 10/19/2021
Recall History
No Recall HistoryFrequently Asked Questions
What is TIBSOVO used for?
Tibsovo (ivosidenib) is an oral tablet used to treat certain types of acute myeloid leukemia and cholangiocarcinoma by inhibiting an enzyme called isocitrate dehydrogenase 1. It works by blocking a specific genetic mutation that can drive the growth of these cancers.
Is TIBSOVO a controlled substance?
TIBSOVO is not classified as a controlled substance by the DEA.
What is the generic name for TIBSOVO?
The generic name for TIBSOVO is ivosidenib. There are no other listed brand versions of ivosidenib.
What is the NDC code for TIBSOVO 250 mg/1?
The NDC (National Drug Code) for TIBSOVO 250 mg/1 is 72694-617, listed by Servier Pharmaceutical LLC.
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)